Valtecne (VLT) H1 2025 earnings summary

Executive summary

• First consolidated financials post-acquisition of 60% stake in Utilità Srl, finalized March 2025, with medical business now 75% of total revenues.

• H1 2025 consolidated revenues reached €19.4M, with EBITDA at €4.6M and net profit at €1.9M; standalone revenues declined 3.9% YoY but value of production increased by 7.7%.

• Medical segment now represents 75% of revenues, reflecting a strategic focus and successful integration of Utilità.

• Adjusted EBITDA margin reached 26.9% on VoP, up 150 bps from organic figure.

• Net debt at €0.9M after acquisition and dividend payments.

Financial highlights

• Consolidated revenues: €19.4M, down 5.3% YoY; medical line stable (+0.4%), industrial down 19.2%.

• Value of Production: €20.3M; organic VoP up 7.7% driven by medical (+26%).

• Adjusted EBITDA: €5.5M (26.9% margin); reported EBITDA: €4.6M (22.6% margin).

• Net income: €1.94M (9.6% of VoP).

• Net financial position: €0.9M net debt at June 30, 2025.

Outlook and guidance

• Orthopaedic market expected to grow 4.3% in 2025, above historical average.

• Medical business order book strong; double-digit growth in value of production targeted for FY25.

• Industrial segment shows signs of stabilization, with premium aerospace segment performing well.

• FY25 volumes expected similar to FY24, with profitability in line with prior year.

• Management expects a further shift toward the medical business and a slight contraction in total group volumes for FY25.